Clinical trial NCT01865032: Evaluation of CL Detect™ Rapid Test to Detect Cutaneous Leishmaniasis
Official title: Pivotal Trials: Evaluation of a Rapid Diagnostic Device, CL Detect™ Rapid Test, for the Diagnosis of Cutaneous Leishmaniasis in the United States
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Skin Diseases
Lead sponsor: U.S. Army Medical Research and Development Command
Sponsor class: FED
Collaborators: name: InBios International, Inc.
First posted: 2013-05-30
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Dermatology clinic

Brief summary: This study is a single-site trial assessing the specificity of CL Detect™ Rapid Test versus the gold standard for Leishmania diagnosis in the US which is microscopic identification of Leishmania amastigotes in a stained lesion sample. Subjects will be patients who present for dermatology consultation with a primarily ulcerated lesion. After informed consent is obtained and the subject is screened for eligibility, 2 diagnostic samples will be collected from the subject's lesion in the following order: 1) one sample will be obtained with a dental broach for use with the CL Detect™ Rapid Test and 2) a second sample will be obtained by scraping for use in the microscopic identification of amastigotes. Samples will be analyzed by microscopy and CL Detect™ Rapid Test. The CL Detect™ Rapid Test will be performed by different operators who are clinical staff members. These staff members, blinded to each other's results, will evaluate the samples from each method independently. Each of the 150 study subjects will be followed administratively to the point where a diagnosis is established (if possible) for their tested lesion, even if that diagnosis is not cutaneous leishmaniasis (CL). If a specific diagnosis cannot be determined for a non-CL lesion, the investigator will assign a "likely etiology" (eg, infectious, oncological, immunological, vascular, or "undetermined/other" origin). Based on the diagnosis determined for each lesion, subjects will be referred for appropriate treatment.


Eligibility criteria: Inclusion Criteria:

* At least 18 years of age
* Subject is able to give written informed consent
* Subject has a skin ulcer that satisfies the following criteria for an index lesion:
* less than 4 months in age
* primarily ulcerative, not purely verrucous or nodular, and does not have clear clinical evidence of cellulitis
* in a location suitable for collecting samples by dental broach and scraping
* In the opinion of the investigator, the subject is capable of understanding and complying with the protocol

Exclusion Criteria:

* Received treatment for leishmaniasis or any treatment to the lesion even if not previously diagnosed as leishmaniasis such as azoles, cryotherapy, imiquimod, thermotherapy, photodynamic therapy, within 2 months prior to signing the consent form, with the exception of mercurochrome

Primary outcomes:
measure: Specificity
timeFrame: 1 hour
Secondary outcomes:
measure: False positive rate
timeFrame: 1 hour
measure: False negative rate
timeFrame: 1 hour
Other outcomes:
Locations:
city: New York
country: United States
facility: Mount Sinai School of Medicine
state: New York
Study officials:
affiliation: Icahn School of Medicine at Mount Sinai
name: Mark Lebwohl, MD
role: PRINCIPAL_INVESTIGATOR
References: